Olmesartán/Amlodipino/Hidroclorotiazida Combix (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing the hormone angiotensin II from causing blood‑vessel constriction and stimulating aldosterone release. This results in vasodilation and reduced sodium‑water retention, contributing to lower blood pressure when combined with the calcium‑channel blocker amlodipine and the thiazide diuretic hydrochlorothiazide.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s blood‑pressure readings, overall health, and response to therapy. The prescriber will select the appropriate tablet strength and frequency to achieve optimal blood‑pressure control while minimizing side effects.

Olmesartan/Amlodipine/HCTZ is generally not recommended during pregnancy because angiotensin‑II receptor blockers can affect fetal development. Safety during breastfeeding has not been established, and the drug may pass into breast milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatments with their healthcare provider.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent therapies, the Olmesartan/Amlodipine/HCTZ combination offers three complementary mechanisms—RAAS blockade, calcium‑channel blockade, and diuresis—allowing more robust blood‑pressure reduction in patients who need multiple agents. It can simplify regimens by reducing pill burden, but clinicians must consider individual tolerability and potential drug interactions.

The tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or other humid environments, and keep out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water. Do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include angioedema (rapid swelling of the face, lips, tongue, or throat), severe hypotension, acute kidney injury, and significant electrolyte disturbances such as hyperkalemia or severe hyponatremia. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden dizziness, or marked changes in urine output.

Patients with known hypersensitivity to any component of the combination should avoid it. It is also contraindicated in individuals with severe hepatic impairment, severe renal dysfunction, or a history of angioedema related to angiotensin‑II receptor blockers. Clinicians should evaluate each patient’s medical history before prescribing.